SHR0302

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Graft-versus-host Disease

Conditions

Graft-versus-host Disease

Trial Timeline

May 29, 2023 → Oct 9, 2023

NCT ID

NCT05856058

About SHR0302

SHR0302 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Graft-versus-host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05856058. Target conditions include Graft-versus-host Disease.

What happened to similar drugs?

0 of 6 similar drugs in Graft-versus-host Disease were approved

Approved (0) Terminated (0) Active (6)

🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3

🔄INCA034176 + Best Available Therapy (BAT)IncytePhase 3

🔄INCA034176IncytePhase 3

🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3

🔄INCA034176 + Placebo + CorticosteroidsIncytePhase 3

🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05856058	Phase 1	Completed	May 29, 2023	Oct 9, 2023	Graft-versus-host Disease
NCT04293029	Phase 1	Completed	May 20, 2020	Dec 30, 2020	Hepatic Impairment
NCT02892370	Phase 1	UNKNOWN	Aug 1, 2016	Oct 1, 2016	Rheumatoid Arthritis

Competing Products

20 competing products in Graft-versus-host Disease

See all competitors

Product	Company	Stage	Hype Score
Alefacept	Astellas Pharma	Phase 2	27
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	32
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	42
PredEver	Novartis	Phase 2	35
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	29
LBH589 + Methylprednisolone	Novartis	Phase 2	27
Panobinostat (LBH589)	Novartis	Phase 1/2	32
Filgrastim	Amgen	Pre-clinical	18
AMG 592	Amgen	Phase 1	29
AMG 592	Amgen	Phase 1	29
BMS-986004 + Sirolimus + Tacrolimus	Bristol Myers Squibb	Phase 1	29
Belumosudil (KD025)	Sanofi	Phase 2	27
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD	Sanofi	Phase 2	35
AAT + Placebo	CSL	Phase 2/3	42
Ruxolitinib + Methylprednisolone	Incyte	Phase 2	39
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)	Incyte	Phase 3	44
Itacitinib + Corticosteroids	Incyte	Phase 1/2	21
Ruxolitinib	Incyte	Pre-clinical	23
Itacitinib + Corticosteroid	Incyte	Phase 1	26
INCA034176	Incyte	Phase 1/2	36